To Develop New Anti-Cancer Drugs, Candidates
Yuhan Corp. announced that it will collaborate with Cyrus Therapeutics, a biopharmaceutical company with targeted proteolysis development technology, to jointly develop new anti-cancer drugs and candidates.
The two companies will conduct basic research on anti-cancer drug development, the joint development of candidate materials, technology transfers, and cooperation in commercialization by making good use of Cyrus Pharmaceuticals’ small molecule-targeted drugs and small molecule degrader development technology.
“We look forward to collaborating with Cyrus Therapeutics, which has strong capabilities in the development of anti-cancer drugs, to develop globally competitive anti-cancer drugs and quickly discover the next Leclaza,” Yuhan Corp. said.
Previously, in 2015, Yuhan Corp. introduced Leclaza, an early-stage lung cancer drug from Korean biotech company Oscotec, and developed a new drug by conducted clinical trials.
After that, Leclaza technology was licensed out to global pharmaceutical giant Janssen for 1.4 trillion won.